Lactiplantibacillus plantarum J26 supplementation improves adiposity-related outcomes in adults with metabolic syndrome via remodeling the gut microbiota

Lactiplantibacillus plantarum J26 supplementation improves adiposity-related outcomes in adults with metabolic syndrome via remodeling the gut microbiota. Download PDF Abstract Preclinical studies have shown that Lactiplantibacillus plantarum J26 (J26) improves metabolic syndrome (MetS)-related parameters, but clinical evidence remains limited. We therefore conducted a 12-week randomized, double-blind, placebo-controlled trial in 110 adults with MetS, who received J26 (5 × 10⁹ CFU/day) or placebo (ChiCTR2400088192).

Compared with placebo, J26 significantly reduced body weight (−0.75 kg, P = 0.021), BMI (−0.29 kg/m², P = 0.021), waist circumference (−1.92 cm, P = 0.023), and body fat (−0.87%, P = 0.003), and enriched Lactobacillus and Bifidobacterium, which partially mediated reductions in adiposity-related outcomes. Although effects on blood pressure, glycemic, and lipid parameters were limited, exploratory clustering identified heterogeneous metabolic responses; responders showed greater metabolic improvements, enrichment of Lactobacillus, Bacteroides, and Anaerobutyricum, and higher baseline dietary quality than non-responders. These exploratory, hypothesis-generating findings require further validation.

J26 may improve adiposity-related outcomes partly through gut microbiota remodeling, while baseline dietary quality may contribute to heterogeneity in broader metabolic benefits. Explore related subjects Discover the latest articles and news in related subjects. Diseases Endocrinology Medical research Microbiology Acknowledgements No funding was received for this research.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with qualified healthcare professionals for medical decisions and treatment options.